Mechanism of action
Modafinil's precise mechanism remains incompletely understood, but it primarily acts as a weak dopamine reuptake inhibitor, increasing extracellular dopamine in the nucleus accumbens and prefrontal cortex. Unlike amphetamines, it does not cause significant dopamine release.
Additional proposed mechanisms include:
- Orexin (hypocretin) activation: Modafinil may enhance orexinergic neurotransmission in the hypothalamus, promoting wakefulness. This is particularly relevant in narcolepsy, where orexin deficiency is a core pathophysiologic feature.
- Histamine release: Animal studies suggest increased histamine release in the hypothalamus, contributing to alertness.
- GABAergic modulation: Modafinil may decrease GABA release in certain brain regions, reducing inhibitory tone and promoting arousal.
- Glutamate enhancement: Some evidence suggests increased glutamatergic activity in wake-promoting regions.
The net effect is sustained wakefulness without the peripheral sympathomimetic effects (tachycardia, hypertension) typical of amphetamines. Modafinil does not significantly affect norepinephrine reuptake, distinguishing it from classical psychostimulants.
- Modafinil is a weak dopamine reuptake inhibitor; it promotes wakefulness without significant peripheral sympathomimetic effects.
- FDA-approved for narcolepsy, obstructive sleep apnea (adjunct to CPAP), and shift work sleep disorder.
- Modafinil induces CYP3A4, reducing hormonal contraceptive efficacy; alternative contraception is required.
- Schedule IV controlled substance with lower abuse potential than amphetamines (Schedule II).
- Rare but serious: Stevens-Johnson syndrome and toxic epidermal necrolysis; discontinue if rash develops.
- Does not treat cataplexy in narcolepsy (use sodium oxybate or antidepressants for cataplexy).
- Contraindicated in patients with LVH or cardiac manifestations of mitral valve prolapse associated with stimulant use.
- Modafinil inhibits CYP2C19, potentially increasing warfarin effect; monitor INR closely.
Indications
Modafinil is FDA-approved for:
- Narcolepsy: Reduces excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (with cataplexy) and type 2 (without cataplexy). It does not treat cataplexy itself.
- Obstructive sleep apnea (OSA): Adjunct therapy for residual EDS despite adequate CPAP therapy. CPAP remains the primary treatment.
- Shift work sleep disorder (SWSD): Improves wakefulness in patients with circadian misalignment due to night or rotating shift work.
Off-label uses
Modafinil is commonly used off-label for:
- ADHD: Particularly when stimulants are contraindicated or ineffective, though not FDA-approved.
- Fatigue in multiple sclerosis: May reduce MS-related fatigue.
- Depression-related fatigue: Augmentation in treatment-resistant depression.
- Cognitive enhancement: Used (and misused) for performance enhancement in healthy individuals, though efficacy and ethics are debated.
Modafinil is not a substitute for sleep and does not reverse cognitive impairment from chronic sleep deprivation.
Pharmacokinetics
- Absorption: Well absorbed orally; peak plasma concentration in 2-4 hours. Food delays absorption but does not affect total bioavailability.
- Distribution: Volume of distribution approximately 0.9 L/kg. Modafinil is approximately 60% protein-bound, primarily to albumin.
- Metabolism: Extensively hepatic via CYP3A4 (major pathway) and CYP2C19. Metabolites include modafinil sulfone and modafinil acid, which are inactive.
- Elimination: Half-life is approximately 12-15 hours. Less than 10% is excreted unchanged in urine. Steady state is reached in 2-4 days.
- Special populations: Severe hepatic impairment reduces clearance; dose reduction is recommended. No significant adjustment needed in renal impairment. Elderly patients may have reduced clearance.
Key pharmacokinetic interaction
Modafinil is a CYP3A4 inducer, which can reduce levels of drugs metabolized by this enzyme, including hormonal contraceptives (see Drug interactions).
Adverse effects
Modafinil is generally well tolerated, with most adverse effects mild to moderate.
Common adverse effects
- Headache (most common, ~34% in trials)
- Nausea
- Nervousness, anxiety
- Insomnia (dose-related; avoid late-day dosing)
- Dizziness
- Dry mouth
- Anorexia and weight loss (less pronounced than with amphetamines)
Serious adverse effects
- Dermatologic reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious. Discontinue immediately if rash develops, especially if accompanied by fever or mucosal involvement.
- Psychiatric symptoms: Anxiety, agitation, mania, hallucinations, and suicidal ideation have been reported, particularly in patients with pre-existing psychiatric disorders.
- Cardiovascular effects: Rare cases of chest pain, palpitations, and hypertension. Use with caution in patients with cardiovascular disease, including left ventricular hypertrophy and mitral valve prolapse.
- Angioedema and anaphylaxis: Rare hypersensitivity reactions.
Multi-organ hypersensitivity reactions
Rare cases of drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported, presenting with rash, fever, lymphadenopathy, and organ involvement (hepatitis, nephritis). Discontinue modafinil if suspected.
Abuse potential
Modafinil is a Schedule IV controlled substance in the US. While it has lower abuse liability than amphetamines, physical dependence and withdrawal (fatigue, hypersomnia) can occur with prolonged use.
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to modafinil or armodafinil
- History of left ventricular hypertrophy or ischemic ECG changes, chest pain, arrhythmia, or other clinically significant manifestations of mitral valve prolapse in association with CNS stimulant use
Warnings and precautions
- Serious rash: Discontinue at first sign of rash unless clearly not drug-related. SJS/TEN risk is higher in children; modafinil is not approved for pediatric use.
- Psychiatric disorders: Screen for history of psychosis, depression, mania, or suicidal ideation. Monitor for emergence or worsening of psychiatric symptoms.
- Cardiovascular disease: Evaluate cardiovascular status before initiating therapy. Monitor blood pressure and heart rate. Consider ECG if indicated.
- Hepatic impairment: Reduce dose in severe impairment.
- Pregnancy: Category C. Limited human data; animal studies show developmental toxicity at high doses. Use only if benefit justifies potential fetal risk.
- Breastfeeding: Unknown if excreted in human milk; use caution.
- Elderly: No specific contraindication, but increased risk of adverse effects due to reduced clearance.
Contraceptive counseling
Women of childbearing potential must be counseled about reduced hormonal contraceptive efficacy (see Drug interactions). Alternative or additional contraceptive methods should be used during treatment and for one month after discontinuation.
Drug interactions
CYP3A4 induction
Modafinil induces CYP3A4, reducing plasma levels of substrates including:
- Hormonal contraceptives: Ethinyl estradiol, progestin levels reduced by ~18-25%. Risk of contraceptive failure. Use alternative or additional non-hormonal contraception.
- Cyclosporine: Reduced immunosuppression; monitor levels.
- Antiretrovirals: Potential reduction in protease inhibitor and NNRTI levels.
- Midazolam, triazolam: Reduced sedative effect.
Induction persists for several weeks after discontinuation.
CYP2C19 inhibition
Modafinil inhibits CYP2C19, potentially increasing levels of:
- Diazepam, phenytoin, propranolol: Monitor for increased effects; dose adjustment may be needed.
- Omeprazole and other proton pump inhibitors: Increased levels possible.
- Warfarin: Increased INR; monitor closely.
Other interactions
- MAO inhibitors: Use with caution; theoretical risk of hypertensive crisis, though less than with amphetamines.
- Alcohol: No pharmacokinetic interaction, but modafinil does not reverse alcohol-induced impairment.
- CNS stimulants: Additive effects; increased risk of cardiovascular and psychiatric adverse effects.
Drug-disease interactions
| Condition | Interaction |
|---|---|
| Severe hepatic impairment | Reduced clearance; lower dose |
| Cardiovascular disease | Monitor closely; may exacerbate |
| Psychiatric disorders | Risk of exacerbation; use caution |
| Tourette syndrome | May worsen tics |
Clinical pearls
- Not a first-line stimulant for ADHD: Modafinil is sometimes used off-label, but methylphenidate and amphetamines remain first-line due to stronger evidence.
- Does not treat cataplexy: Unlike sodium oxybate or certain antidepressants (venlafaxine, SSRIs), modafinil has no effect on cataplexy in narcolepsy.
- Lower abuse potential than amphetamines: Schedule IV vs. Schedule II for methylphenidate. Useful alternative when diversion or abuse is a concern.
- Armodafinil is the R-enantiomer: Armodafinil has a longer half-life and may provide more sustained wakefulness later in the day. Dosing is not interchangeable (modafinil 200 mg ≈ armodafinil 150 mg).
- Timing matters: Take in the morning for narcolepsy/OSA; 1 hour before shift start for SWSD. Late dosing causes insomnia.
- Baseline cardiovascular assessment: Especially important in patients over 40 or with risk factors. Avoid in symptomatic mitral valve prolapse or LVH.
- Cognitive enhancement myth: While modafinil improves alertness in sleep-deprived individuals, evidence for cognitive enhancement in well-rested, healthy people is weak and inconsistent.
- Monitoring: Periodic assessment of continued need, blood pressure, heart rate, and psychiatric status. No routine laboratory monitoring required.
- Withdrawal: Abrupt discontinuation may cause fatigue and hypersomnia, but withdrawal is generally mild. Tapering is not usually necessary.
- Military and aviation use: Modafinil has been studied and used by military forces to sustain alertness during prolonged operations. FAA permits modafinil use for approved indications with appropriate oversight.
Practice questions
1. A 28-year-old woman with narcolepsy is started on modafinil 200 mg daily. She also takes an oral contraceptive pill containing ethinyl estradiol and norgestimate. Four months later, she presents with a positive pregnancy test. She reports adherence to both medications. Which of the following best explains this outcome?
2. A 35-year-old man with obstructive sleep apnea on CPAP therapy continues to have excessive daytime sleepiness. Modafinil is started. Five days later, he develops a diffuse maculopapular rash with fever and facial edema. Laboratory studies show eosinophilia and elevated transaminases. Which of the following is the most appropriate next step?
3. A 42-year-old woman with narcolepsy reports persistent cataplexy triggered by laughter, occurring 3-4 times weekly. She is currently taking modafinil 200 mg each morning, which has improved her daytime sleepiness. Which of the following is the most appropriate modification to her treatment?
Frequently asked questions
How does modafinil work?
Modafinil primarily works as a weak dopamine reuptake inhibitor, increasing dopamine levels in wake-promoting brain regions. It may also enhance orexin (hypocretin) signaling, increase histamine release, and modulate GABAergic and glutamatergic neurotransmission. Unlike amphetamines, modafinil does not cause significant dopamine release or norepinephrine reuptake inhibition, which explains its lower abuse potential and fewer cardiovascular side effects.
What are the side effects of modafinil?
The most common side effects are headache, nausea, nervousness, and insomnia. Serious but rare adverse effects include Stevens-Johnson syndrome, toxic epidermal necrolysis, and multi-organ hypersensitivity reactions; any rash warrants immediate discontinuation. Psychiatric symptoms such as anxiety, agitation, and rarely psychosis can occur. Modafinil induces CYP3A4, reducing hormonal contraceptive effectiveness, which is a critical counseling point for women of childbearing age.
Is modafinil a controlled substance?
Yes, modafinil is a Schedule IV controlled substance in the United States. This classification reflects its potential for abuse and dependence, though significantly lower than Schedule II stimulants like amphetamines and methylphenidate. Physical dependence can develop with chronic use, and abrupt discontinuation may cause withdrawal symptoms such as fatigue and hypersomnia. However, modafinil is generally considered to have a more favorable safety and abuse profile compared to traditional stimulants.
Modafinil vs methylphenidate — what is the difference?
Modafinil is a weak dopamine reuptake inhibitor with lower abuse potential (Schedule IV), used primarily for sleep disorders like narcolepsy and shift work sleep disorder. Methylphenidate is a stronger dopamine and norepinephrine reuptake inhibitor (Schedule II), FDA-approved for ADHD and narcolepsy, with higher efficacy for ADHD but greater abuse potential. Modafinil causes fewer cardiovascular side effects and has minimal peripheral sympathomimetic activity compared to methylphenidate.
Can you take modafinil with birth control pills?
Modafinil induces CYP3A4, which reduces plasma levels of ethinyl estradiol and progestins by approximately 18-25%, significantly increasing the risk of contraceptive failure. Women using hormonal contraceptives (pills, patches, rings) must use alternative or additional non-hormonal contraceptive methods during modafinil treatment and for one month after discontinuation. This interaction is a high-yield clinical pearl and a common reason for treatment failure or unintended pregnancy.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06BA07
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.